PTC TherapeuticsPTCT
PTCT
About: PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Employees: 995
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
126% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $2.51M
18% more capital invested
Capital invested by funds: $2.49B [Q2] → $2.93B (+$437M) [Q3]
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
2% more funds holding
Funds holding: 197 [Q2] → 201 (+4) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 70
3.32% less ownership
Funds ownership: 106.07% [Q2] → 102.76% (-3.32%) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
29%
downside
Avg. target
$56
23%
upside
High target
$71
57%
upside
9 analyst ratings
5 positive
56%
2 neutral
22%
2 negative
22%
Morgan Stanley Jeffrey Hung 35% 1-year accuracy 6 / 17 met price target | 48%upside $67 | Overweight Upgraded | 13 Dec 2024 |
Citigroup David Lebowitz 45% 1-year accuracy 10 / 22 met price target | 29%downside $32 | Sell Maintained | 4 Dec 2024 |
Goldman Sachs Paul Choi 30% 1-year accuracy 3 / 10 met price target | 7%downside $42 | Sell Maintained | 4 Dec 2024 |
UBS Colin Bristow 13% 1-year accuracy 2 / 16 met price target | 57%upside $71 | Buy Maintained | 3 Dec 2024 |
Baird Joel Beatty 48% 1-year accuracy 21 / 44 met price target | 54%upside $70 | Outperform Maintained | 3 Dec 2024 |
Financial journalist opinion
Based on 14 articles about PTCT published over the past 30 days
Neutral
PRNewsWire
2 days ago
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J. , Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.
Neutral
PRNewsWire
6 days ago
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
- If approved, vatiquinone would be the first and only authorized therapy for children with FA - - PTC's fourth approval application submitted to FDA in 2024 - WARREN, N.J. , Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA).
Neutral
PRNewsWire
1 week ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J. , Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees.
Positive
Zacks Investment Research
3 weeks ago
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.
Positive
Investopedia
3 weeks ago
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS).
Positive
Benzinga
3 weeks ago
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules.
Positive
Investors Business Daily
3 weeks ago
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Positive
Reuters
3 weeks ago
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder.
Neutral
PRNewsWire
3 weeks ago
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales - - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study - - PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules.
Negative
Benzinga
4 weeks ago
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
Charts implemented using Lightweight Charts™